These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26018248)

  • 1. C-Terminal Clostridium perfringens Enterotoxin-Mediated Antigen Delivery for Nasal Pneumococcal Vaccine.
    Suzuki H; Watari A; Hashimoto E; Yonemitsu M; Kiyono H; Yagi K; Kondoh M; Kunisawa J
    PLoS One; 2015; 10(5):e0126352. PubMed ID: 26018248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired airway mucociliary function reduces antigen-specific IgA immune response to immunization with a claudin-4-targeting nasal vaccine in mice.
    Suzuki H; Nagatake T; Nasu A; Lan H; Ikegami K; Setou M; Hamazaki Y; Kiyono H; Yagi K; Kondoh M; Kunisawa J
    Sci Rep; 2018 Feb; 8(1):2904. PubMed ID: 29440671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection.
    Hanniffy SB; Carter AT; Hitchin E; Wells JM
    J Infect Dis; 2007 Jan; 195(2):185-93. PubMed ID: 17191163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.
    Wang D; Lu J; Yu J; Hou H; Leenhouts K; Van Roosmalen ML; Gu T; Jiang C; Kong W; Wu Y
    Immunol Invest; 2018 May; 47(4):403-415. PubMed ID: 29498560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice.
    Tada R; Suzuki H; Takahashi S; Negishi Y; Kiyono H; Kunisawa J; Aramaki Y
    Int Immunopharmacol; 2018 Aug; 61():385-393. PubMed ID: 29945026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.
    Xin W; Li Y; Mo H; Roland KL; Curtiss R
    Infect Immun; 2009 Oct; 77(10):4518-28. PubMed ID: 19687204
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The safety of a mucosal vaccine using the C-terminal fragment of Clostridium perfringens enterotoxin.
    Suzuki H; Kakutani H; Kondoh M; Watari A; Yagi K
    Pharmazie; 2010 Oct; 65(10):766-9. PubMed ID: 21105580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae.
    Kong IG; Sato A; Yuki Y; Nochi T; Takahashi H; Sawada S; Mejima M; Kurokawa S; Okada K; Sato S; Briles DE; Kunisawa J; Inoue Y; Yamamoto M; Akiyoshi K; Kiyono H
    Infect Immun; 2013 May; 81(5):1625-34. PubMed ID: 23460513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The application of an alanine-substituted mutant of the C-terminal fragment of Clostridium perfringens enterotoxin as a mucosal vaccine in mice.
    Suzuki H; Kondoh M; Kakutani H; Yamane S; Uchida H; Hamakubo T; Yagi K
    Biomaterials; 2012 Jan; 33(1):317-24. PubMed ID: 21983135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization and Specification of a Trivalent Protein-Based Pneumococcal Vaccine Formulation Using an Adjuvant-Free Nanogel Nasal Delivery System.
    Yuki Y; Uchida Y; Sawada SI; Nakahashi-Ouchida R; Sugiura K; Mori H; Yamanoue T; Machita T; Honma A; Kurokawa S; Mukerji R; Briles DE; Akiyoshi K; Kiyono H
    Mol Pharm; 2021 Apr; 18(4):1582-1592. PubMed ID: 33621107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.
    Tostes RO; Rodrigues TC; da Silva JB; Schanoski AS; Oliveira ML; Miyaji EN
    PLoS One; 2017; 12(1):e0170157. PubMed ID: 28103277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.
    Moore QC; Bosarge JR; Quin LR; McDaniel LS
    Vaccine; 2006 Jul; 24(29-30):5755-61. PubMed ID: 16759765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multivalent Pneumococcal Protein Vaccines Comprising Pneumolysoid with Epitopes/Fragments of CbpA and/or PspA Elicit Strong and Broad Protection.
    Chen A; Mann B; Gao G; Heath R; King J; Maissoneuve J; Alderson M; Tate A; Hollingshead SK; Tweten RK; Briles DE; Tuomanen EI; Paton JC
    Clin Vaccine Immunol; 2015 Oct; 22(10):1079-89. PubMed ID: 26245351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia.
    Kataoka K; Fujihashi K; Oma K; Fukuyama Y; Hollingshead SK; Sekine S; Kawabata S; Ito HO; Briles DE; Oishi K
    Infect Immun; 2011 Jul; 79(7):2819-28. PubMed ID: 21536790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broad protective immune responses elicited by bacterium-like particle-based intranasal pneumococcal particle vaccine displaying PspA2 and PspA4 fragments.
    Lu J; Guo J; Wang D; Yu J; Gu T; Jiang C; Kong W; Wu Y
    Hum Vaccin Immunother; 2019; 15(2):371-380. PubMed ID: 30235046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.